Sistemas aquosos bifásicos uma ferramenta sustentável para a extração de ácido clavulânico a partir de diferentes fontes

O ácido clavulânico (AC) é um inibidor de β-lactamases que tem vindo a ser largamente utilizado na área médica. Embora seja de extrema importância, o desenvolvimento de processos alternativos de produção e purificação é ainda insignificante, sendo fundamental o estudo de técnicas de extração mais biocompatíveis, como os Sistemas Aquosos Bifásicos (SABs). Assim, este trabalho objetivou o estudo de Sistemas Aquosos Bifásicos baseados em polímeros como uma ferramenta alternativa para a extração de AC. Foram testados dois SPAB compostos por Polietileno Glicol (PEG) com massa molecular (M) de 4000 g/mol e Poliacrilato de Sódio de 8000 g/mol, nos quais foi alterado o eletrólito indutor da formação de fases, em particular, sulfato de sódio (Na2SO4,) e cloreto de sódio (NaCl). Ademais, este trabalho visou também avaliar a eficiência de extração do AC, bem como compreender o efeito dos contaminantes no processo de migração. Para tal, foi avaliada a extração do AC a partir de três fontes distintas: solução pura (99,9%); solução comercial (60%); diretamente a partir do sobrenadante de um meio fermentando de Streptomyces clavuligerus. Os resultados obtidos demonstraram que independentemente da fonte inicial do AC, ambos os SABs poliméricos promoveram uma partição preferencial do AC para a fase rica em PEG, sendo o coeficiente de partição maior nos sistemas com Na2SO4 do que com NaCl. Após identificar a grande capacidade de partição de AC, o SAB com PEG/NaPA/Na2SO4 foi também utilizado para avaliar a partição de proteínas presente no meio fermentado, sendo também obtida uma preferencial partição destas para a fase rica em PEG. Assim, apesar da baixa capacidade de purificação de AC frente a proteínas contaminantes, os SABs estudados demonstraram que podem ser uma técnica alternativa sustentável e bastante econômica para uma etapa inicial de clarificação/concentração de bioprodutos a partir de caldos fermentados

Production and characterization of recombinant Aliivibrio fischeri L-Asparaginase with low L-Glutamine affinity: a potential antileukemic drug obtained by genetic engineering

L-Asparaginase has been successfully applied in the treatment of lymphoid malignancies. Some limitations in the use of the commercial preparations of this drug include several side effects that may be correlated to L-Glutaminase activity, as immunosuppressive effects (Castro et al., 2021). The objective of this study was to evaluate the characteristics of a novel engineered Aliivibrio fischeri L-asparaginase type II expressed by Bacillus subtilis. Cultivations were carried out in shaken flasks at 30 ºC, 200 rpm, 24 h, using Luria-Bertani medium. Intracellular enzyme was recovered by sonication and enzymatic activities were evaluated by Nessler colorimetric method (Mashburn; Wriston, 1963). Recovered enzymatic extracts achieved L-Asparaginase activity up to 1.43 U.mL-1 at optimum pH 7.5. Substrate affinity was much higher for L-Asparagine than for L-Glutamine (Km= 1.226 mmol.L-1 and Km= 28.584 mmol.L-1, respectively), which indicate the potential application of the recombinant enzyme as biopharmaceutical.publishe

L-Asparaginase

L-Asparaginase (ASNase, EC 3.5.1.1) is a tetrameric aminohydrolase enzyme that catalyses the hydrolysis of the amino acid L-Asparagine into ammonia and L-aspartic acid. ASNase is present in different organisms such as bacteria, fungi, plant tissues and algae. ASNase is used in the pharmaceutical field as an anticancer drug for the treatment of acute lymphoblastic leukemia (ALL) and other malignant diseases such as Hodgkin’s disease. In the food sector, ASNase is used to prevent the formation of acrylamide, a toxic compound formed when starch-rich foods are cooked at temperatures above 100 °C. ASNase can also be used as a biosensor for the detection of L-asparagine levels.publishe

Sustainable lysis of Bacillus subtilis biomass to recover the biopharmaceutical L-asparaginase

The first-line biopharmaceutical used to treat Acute lymphoblastic leukemia (ALL), Oncaspar, is based on the enzyme L-asparaginase (ASNase), and has annual sales of ca. USD $100 million. In addition to other sources, genetically modified Bacillus subtilis is regarded as one of the most promising hosts for the ASNase production. The Aliivibrio fischeri ASNase type II, which has anti-tumour activity due its higher specific affinity for L-asparagine, expressed in B. subtillis is located in the periplasm. Therefore, cell lysis is required for the ASNase recovery. Nevertheless, typical cell lysis approaches, e.g. chemical methods with surfactants lead to some biocompatibility concerns and the need of extra purification steps. To overcome this drawback, in this work, ultrasound sonication (USS) conditions were studied to develop a greener and more biocompatible method for ASNase recovery from B. subtilis cell lysis. The USS cell lysis was optimized regarding the amplitude of USS pulse, number of lysis cycles and mass of cells/volume of solvent ratio. The identification and quantification of ASNase and major impurities present in the cell extract after lysis were investigated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion high-performance liquid chromatography (SE-HPLC). ASNase activity was determined by monitoring the hydrolysis of the substrate, L-asparagine. The results obtained show that the ideal conditions for B. subtilis cell lysis are an amplitude of USS pulse of 60%, 40 cycles of lysis and 10 mL of phosphatebuffered saline (PBS) per 1 g of cells. Overall, an optimized sustainable B. subtilis cell lysis method was developed, avoiding the use of surfactants and with low energy consumption.publishe

Supported ionic liquid materials for L-asparaginase bioconjugation

Since the average life expectancy is increasing, several fatal diseases usually related to aging, such as cancer, heart and neurological diseases have become predominant. Biopharmaceuticals, namely nucleic-acid-based products, antibodies, recombinant proteins and enzymes are fundamental to overcome these age-related diseases. Actually, the gold standard enzyme for the treatment of acute chronic lymphoblastic leukemia (ALL) is L-asparaginase (ASNase). Hence, the reusability of this high-priced drug enables the cost reduction of treatments, which allows its routinely use by a widespread population. In this work, functionalized nanomaterials, namely supported ionic liquid materials (SILs) based on silica, formerly described in the literature for the separation of natural compounds from vegetable biomass, were studied as a cost effective support for ASNase immobilization and reuse. Commercial ASNase was used for preliminary tests. Several experimental immobilization conditions, such as pH, contact time, ASNase concentration and SILs recyclability were assessed and optimized, regarding the immobilized ASNase activity, assessed by Nessler reaction, which quantifies the amount of ammonium released after the enzymatic reaction with L-asparagine and immobilization yield. In fact, ASNase immobilization onto the SILs was successfully achieved with an immobilized ASNase activity ranging from 0.6 to 0.9 U of enzyme per mg of SILs under the optimum immobilization conditions. Moreover, all SILs allowed 5 cycles of reaction, while keeping more than 75% of initial ASNase activity. Through the envisioned immobilization strategy, process costs will be considerably reduced, which can lead to a wider use of ASNase in diverse fields of application.publishe

Improvement of carotenoids production from Rhodotorula glutinis CCT-2186

Rhodotorula strains can produce industrial valuable bioproducts. In this work, the production of carotenoids, and lipids by Rhodotorula glutinis using different nitrogen sources was evaluated. Two statistical experimental designs were applied to improve carotenoid production: a first 25−1 fractional factorial design evaluating the influence of independent variables pH, nitrogen source, glucose, KH2PO4 and MgSO4 concentration; a second 22 central factorial design to optimize the effect of pH and nitrogen sources. After the optimization using two statistical designs, a culture mediium composed of (in g/L) glucose (10), asparagine (10), NH4NO3 (4), KH2PO4 (0.52), MgSO4 (0.52) was found as the best for the production of carotenoids at a pH 5 and 30 °C. The best bioprocess was scaled-up to a 5 L stirred-tank bioreactor. The change to a bioreactor allowed to improve aeration and agitation conditions, and consequently, increasing the production yields (m/v) in, approximately, 25.83 %, 11.88 %, 24.50 % and 10.32 % for β-carotene, torularhodin, torulene and lipids, respectively. The combined supplementation of the culture media with both organic (asparagine) and inorganic nitrogen (ammonium nitrate) sources was primordial for enhancing the carotenogenesis. R. glutinis are very efficient in the production of valuable carotenoids and lipids, presenting high potential of yeast for the industrial production of more sustainable cosmetic, pharmaceutical, and food products.publishe

Recent strategies and applications for l-asparaginase confinement

l-asparaginase (ASNase, EC 3.5.1.1) is an aminohydrolase enzyme with important uses in the therapeutic/pharmaceutical and food industries. Its main applications are as an anticancer drug, mostly for acute lymphoblastic leukaemia (ALL) treatment, and in acrylamide reduction when starch-rich foods are cooked at temperatures above 100 °C. Its use as a biosensor for asparagine in both industries has also been reported. However, there are certain challenges associated with ASNase applications. Depending on the ASNase source, the major challenges of its pharmaceutical application are the hypersensitivity reactions that it causes in ALL patients and its short half-life and fast plasma clearance in the blood system by native proteases. In addition, ASNase is generally unstable and it is a thermolabile enzyme, which also hinders its application in the food sector. These drawbacks have been overcome by the ASNase confinement in different (nano)materials through distinct techniques, such as physical adsorption, covalent attachment and entrapment. Overall, this review describes the most recent strategies reported for ASNase confinement in numerous (nano)materials, highlighting its improved properties, especially specificity, half-life enhancement and thermal and operational stability improvement, allowing its reuse, increased proteolysis resistance and immunogenicity elimination. The most recent applications of confined ASNase in nanomaterials are reviewed for the first time, simultaneously providing prospects in the described fields of application.publishe

Reusability of L-asparaginase immobilized on silica-based supported ionic liquids

L-asparaginase (ASNase) is an aminohydrolase enzyme used as an anticancer drug, e.g. in the treatment of acute lymphoblastic leukemia, in acrylamide reduction and in biosensing. Nevertheless, its low stability and thermolability, and susceptibility to proteases, hinder its application in the health and food industries. Hence, the improvement of its properties through efficient immobilization methods is in high demand. Thus, this work aims the development of silica-based supported ionic liquids (SILs) for the ASNase immobilization to improve its stability and enable its reusability. While activated silica with no ILs only kept total initial ASNase activity during the first cycle of reaction, SILs allowed 5 cycles of reaction, keeping 82% of initial ASNase activity, reinforcing their potential as alternative enzymatic supports.publishe

Carbon nanomaterials for the purification of antileukemic drugs

Getting older is the biggest risk factor for most fatal diseases, including cancer, heart disease and Alzheimer. To overcome such age-related society diseases, it is crucial to optimize the production and purification of biopharmaceuticals, such as nucleic acid-based products, antibodies and recombinant proteins and enzymes. Low cost production combined with high purity levels allow their routinely use by a widespread population. Continuous progresses have been made for the development of recombinant therapeutic enzymes. L-asparaginase (LA) is an antileukemic biopharmaceutical enzyme of current high-cost. LA is produced via fermentation and its purification usually comprises several steps that account up to 80% of its total production cost (1). This work aims to develop sustainable technologies to extract and purify LA. Reusable functionalized nanomaterials, namely carbon nanomaterials (CNTs), are used as cost-effective purification techniques for the target enzyme. Initially, the synthesis and modification of CNTs was performed. Different CNTs were obtained and used for the purification of LA. Commercial LA was used for the first purification tests, in order to understand the behaviour of the enzyme in contact with the nanomaterial. Experimental conditions, such as pH, and material/LA ratio, contact time were optimized. LA activity was quantified by Nessler reaction (2). The first results reveal a total adsorption of LA by the CNTs. Depending on the CNT functionalization/ treatment, different values of recovered activity of LA were obtained. The modified CNTs are shown to be very promising nanomaterials for the purification of LA. The LA was easily attached to CNTs by adsorption under mild conditions. CNTs supports can be a real alternative for a single step immobilization/purification of LA.publishe